All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are novel strategies to treat higher-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, What are novel strategies to treat higher-risk MDS?

What are novel strategies to treat higher-risk MDS?

Sekeres firstly suggests a new method to define MDS risk by combining the IPSS with genetic mutational status. He then evaluates novel strategies for higher-risk MDS, including combination therapies and molecular profiling.

 

Share: